Table 1 Baseline patient characteristics... | American Society of Hematology

Table 1

Baseline patient characteristics grouped by the datasets used for analysis

Dataset	No. of patients	No. of kinetics	Laboratory parameter	Baseline values			Mean age, y (range)	Sex
Dataset	No. of patients	No. of kinetics	Laboratory parameter	Mean	Median	Range	Mean age, y (range)	Sex
Set 1	41	47*	CD4 (cells/μL)	339	264	59-1013	44 (20-60)	39 male
			CD8 (cells/μL)	951	808	180-2657		2 female
			log₁₀VL (copies/mL)	3.06	2.47	< 1.70-6.15		2 female
Set 2†	41	41	CD4 (cells/μL)	313	261	59-800	44 (20-60)	39 male
			CD8 (cells/μL)	959	808	180-2657		2 female
			log₁₀VL (copies/mL)	3.24	3.06	< 1.70-6.15		2 female
Set 3‡	22	22	CD4 (cells/μL)	300	235	78-636	44 (20-60)	21 male
			CD8 (cells/μL)	976	739	180-2657		1 female
			log₁₀VL (copies/mL)	2.71	1.82	< 1.70-6.15
			% CD4: RA⁺27⁺	29	25	3-68
			% CD4: RA⁻27⁺	51	50	28-78
			% CD4: RA⁺27⁻	5	5	1-21
			% CD4: RA⁻27⁻	15	11	1-35
			% CD4: DR⁺38⁺	11	9	3-22
			% CD8: RA⁺27⁺	30	27	6-83
			% CD8: RA⁻27⁺	32	27	11-63
			% CD8: RA⁺27⁻	19	18	2-37
			% CD8: RA⁻27⁻	19	16	1-53
			% CD8: DR⁺38⁺	19	16	2-55

Dataset	No. of patients	No. of kinetics	Laboratory parameter	Baseline values			Mean age, y (range)	Sex
Dataset	No. of patients	No. of kinetics	Laboratory parameter	Mean	Median	Range	Mean age, y (range)	Sex
Set 1	41	47*	CD4 (cells/μL)	339	264	59-1013	44 (20-60)	39 male
			CD8 (cells/μL)	951	808	180-2657		2 female
			log₁₀VL (copies/mL)	3.06	2.47	< 1.70-6.15		2 female
Set 2†	41	41	CD4 (cells/μL)	313	261	59-800	44 (20-60)	39 male
			CD8 (cells/μL)	959	808	180-2657		2 female
			log₁₀VL (copies/mL)	3.24	3.06	< 1.70-6.15		2 female
Set 3‡	22	22	CD4 (cells/μL)	300	235	78-636	44 (20-60)	21 male
			CD8 (cells/μL)	976	739	180-2657		1 female
			log₁₀VL (copies/mL)	2.71	1.82	< 1.70-6.15
			% CD4: RA⁺27⁺	29	25	3-68
			% CD4: RA⁻27⁺	51	50	28-78
			% CD4: RA⁺27⁻	5	5	1-21
			% CD4: RA⁻27⁻	15	11	1-35
			% CD4: DR⁺38⁺	11	9	3-22
			% CD8: RA⁺27⁺	30	27	6-83
			% CD8: RA⁻27⁺	32	27	11-63
			% CD8: RA⁺27⁻	19	18	2-37
			% CD8: RA⁻27⁻	19	16	1-53
			% CD8: DR⁺38⁺	19	16	2-55

Six patients received a BrdU infusion before and after an effective HAART therapy.

First infusion for all 41 patients.

Patients for whom the BrdU kinetics of the subsets were also available.